Prelude Therapeutics annual operating income
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Operating Income Growth & History (PRLD)
Prelude Therapeutics's operating income was −$104.6M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$104.6M | $35.1M | — |
| 2024 | 2024-12-31 | −$139.7M | −$7.4M | — |
| 2023 | 2023-12-31 | −$132.3M | −$8.7M | — |
| 2022 | 2022-12-31 | −$123.5M | −$9.8M | — |
| 2021 | 2021-12-31 | −$113.7M | −$55.0M | — |
| 2020 | 2020-12-31 | −$58.8M | −$30.7M | — |
| 2019 | 2019-12-31 | −$28.1M | — | — |
Prelude Therapeutics quarterly operating income
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.5M | $16.7M | — |
| Q1 2026 | 2026-03-31 | −$14.2M | $20.4M | — |
| Q4 2025 | 2025-12-31 | −$17.3M | $16.5M | — |
| Q3 2025 | 2025-09-30 | −$20.4M | $14.0M | — |
| Q2 2025 | 2025-06-30 | −$32.2M | $5.0M | — |
| Q1 2025 | 2025-03-31 | −$34.6M | −$263,000 | — |
| Q4 2024 | 2024-12-31 | −$33.8M | $3.5M | — |
| Q3 2024 | 2024-09-30 | −$34.4M | −$991,000 | — |
| Q2 2024 | 2024-06-30 | −$37.2M | −$4.8M | — |
| Q1 2024 | 2024-03-31 | −$34.3M | −$5.2M | — |
| Q4 2023 | 2023-12-31 | −$37.4M | −$4.0M | — |
| Q3 2023 | 2023-09-30 | −$33.4M | −$3.0M | — |
| Q2 2023 | 2023-06-30 | −$32.4M | −$2.9M | — |
| Q1 2023 | 2023-03-31 | −$29.1M | $1.2M | — |
| Q4 2022 | 2022-12-31 | −$33.4M | −$375,000 | — |
| Q3 2022 | 2022-09-30 | −$30.4M | $430,000 | — |
| Q2 2022 | 2022-06-30 | −$29.5M | −$1.5M | — |
| Q1 2022 | 2022-03-31 | −$30.3M | −$8.3M | — |
| Q4 2021 | 2021-12-31 | −$33.0M | −$13.6M | — |
| Q3 2021 | 2021-09-30 | −$30.8M | −$12.7M | — |
| Q2 2021 | 2021-06-30 | −$27.9M | −$16.5M | — |
| Q1 2021 | 2021-03-31 | −$22.0M | −$12.2M | — |
| Q4 2020 | 2020-12-31 | −$19.4M | — | — |
| Q3 2020 | 2020-09-30 | −$18.1M | −$11.3M | — |
| Q2 2020 | 2020-06-30 | −$11.4M | — | — |
| Q1 2020 | 2020-03-31 | −$9.7M | — | — |
| Q3 2019 | 2019-09-30 | −$6.9M | — | — |
Prelude Therapeutics operating income trends
Over the last five fiscal years, Prelude Therapeutics's operating income decreased from −$58.8M to −$104.6M, a change of −$45.8M. The latest reported quarter, Q2 2026, shows −$15.5M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...